Elanco Animal Health Inc Stock Research

Market Summary

USD8.99+0.17

Delayedas of 27 Mar 2023, 01:40 pm

1.93%

ELAN Alerts

2 major insider buys recently.
Big fall in Revenue (Y/Y)
Big jump in Earnings (Y/Y)
Losses in recent quarter

ELAN Stock Price

ELAN RSI Chart

ELAN Valuation

Market Cap

4.2B

Price/Earnings (Trailing)

-53.63

Price/Sales (Trailing)

0.95

EV/EBITDA

11.44

Price/Free Cashflow

13.28

ELAN Price/Sales (Trailing)

ELAN Profitability

EBT Margin

-1.63%

Return on Equity

-1.07%

Return on Assets

-0.5%

Free Cashflow Yield

7.53%

ELAN Fundamentals

ELAN Revenue

Revenue (TTM)

4.4B

Revenue Y/Y

-11.86%

Revenue Q/Q

-4.57%

ELAN Earnings

Earnings (TTM)

-78.0M

Earnings Y/Y

47.62%

Earnings Q/Q

-12.24%

Price Action

52 Week Range

8.6827.61

(Low)(High)

Last 7 days

-8.5%

Last 30 days

-27.9%

Last 90 days

-24.7%

Trailing 12 Months

-67.9%

ELAN Financial Health

Current Ratio

1.93

Debt/Equity

0.81

Debt/Cashflow

0.08

ELAN Investor Care

Shares Dilution (1Y)

0.24%

Diluted EPS (TTM)

-0.16

Peers (Alternatives to Elanco Animal Health)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	401.1B	94.9B	-3.25%	-11.17%	22.36	4.23	1.25%	-14.07%
LLY	302.8B	28.5B	2.15%	17.94%	48.48	10.61	0.79%	11.88%
MRK	272.8B	59.3B	-3.99%	33.34%	17.88	4.63	21.72%	11.27%
PFE	226.5B	100.3B	-4.70%	-21.30%	7.22	2.26	23.43%	42.74%
BMY	143.9B	46.2B	-5.09%	-4.47%	22.74	3.12	-0.49%	-9.54%
MID-CAP
PRGO	4.6B	4.5B	-7.51%	-10.48%	-32.41	1.02	7.56%	-104.06%
RETA	3.1B	2.2M	88.62%	133.17%	-10.04	1.4K	-80.71%	-4.88%
SMALL-CAP
SUPN	1.9B	667.2M	-7.26%	10.85%	31.38	2.86	15.09%	13.64%
TLRY	1.6B	602.5M	-7.75%	-62.41%	-2.78	2.67	18.18%	-18.59%
CGC	923.6M	478.9M	-20.50%	-75.95%	-0.29	1.93	-31.50%	-634.70%
INVA	785.3M	285.2M	-7.87%	-42.24%	3.57	2.75	-27.21%	-40.28%
CRON	738.3M	114.5M	-10.60%	-51.38%	-4.38	6.45	27.90%	57.40%
ACRS	534.2M	29.8M	-36.88%	-54.59%	-6.15	17.95	340.05%	4.35%
OCUL	379.8M	51.5M	-18.81%	-6.64%	-5.35	7.38	18.32%	-984.05%
ENDP	94.1M	2.3B	-43.99%	-88.43%	-0.03	0.04	-22.53%	-376.66%

Financials for Elanco Animal Health

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-2.9%	4,411	4,543	4,646	4,748	4,765
S&GA Expenses	-1.8%	1,265	1,288	1,332	1,374	1,402
R&D Expenses	-3.6%	321	333	349	361	369
EBITDA	4.7%	851	813	727	501	-
EBITDA Margin	7.8%	0.19*	0.18*	0.16*	0.11*	-
Earnings Before Taxes	33.9%	-72.00	-109	-197	-415	-566
EBT Margin	32.0%	-0.02*	-0.02*	-0.04*	-0.09*	-
Interest Expenses	3.0%	241	234	234	227	236
Net Income	39.1%	-78.00	-128	-183	-371	-480
Net Income Margin	37.2%	-0.02*	-0.03*	-0.04*	-0.08*	-
Free Cahsflow	-40.0%	315	525	426	272	-

* denotes actual numbers (not divided by Millions)
Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	3.6%	15,491	14,948	15,601	16,251	16,483
Current Assets	4.0%	3,279	3,154	3,307	3,194	3,276
Cash Equivalents	-25.0%	345	460	507	342	638
Inventory	14.8%	1,538	1,340	1,334	1,345	1,373
Net PPE	6.7%	999	936	961	987	1,061
Goodwill	4.8%	5,993	5,716	5,898	6,116	6,172
Liabilities	0.0%	8,202	8,203	8,461	8,639	8,945
Current Liabilities	5.5%	1,702	1,613	1,338	1,307	1,643
Long Term Debt	-2.7%	5,901	6,063	6,134	6,319	-
LT Debt, Current	-1.5%	388	394	56.00	61.00	294
LT Debt, Non Current	-1.1%	5,448	5,507	6,007	6,073	6,025
Shareholder's Equity	8.1%	7,289	6,745	7,140	7,612	7,538
Retained Earnings	-8.7%	-1,057	-972	-923	-901	-949
Additional Paid-In Capital	0.2%	8,738	8,724	8,712	8,699	8,696
Accumulated Depreciation	3.9%	723	696	688	670	1,041
Shares Outstanding	0.0%	474	474	474	474	473

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-31.7%	452	662	562	399	483
Share Based Compensation	-4.8%	59.00	62.00	66.00	65.00	66.00
Cashflow From Investing	-1.1%	-179	-177	-581	-569	-530
Cashflow From Financing	-30.4%	-549	-421	-21.00	8.00	210

Risks for ELAN

What is the probability of a big loss on ELAN?

66.4%

Probability that Elanco Animal Health stock will be more than 20% underwater in next one year

47.1%

Probability that Elanco Animal Health stock will be more than 30% underwater in next one year.

37.4%

Probability that Elanco Animal Health stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ELAN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Elanco Animal Health was unfortunately bought at previous high price.

Drawdowns

Returns for ELAN

Cumulative Returns on ELAN

-22.0%

3-Year Cumulative Returns

Which funds bought or sold ELAN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-10	VICTORY CAPITAL MANAGEMENT INC	added	13.72	364,863	3,406,860	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-98.69	-1,687,000	21,000	-%
2023-03-02	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	new	-	6,550	6,550	-%
2023-03-01	BENNICAS & ASSOCIATES, INC.	sold off	-100	-191,000	-	-%
2023-02-28	Voya Investment Management LLC	added	0.4	-7,629	703,371	-%
2023-02-24	NATIXIS	added	178	10,112,500	15,926,500	0.09%
2023-02-24	SRS Capital Advisors, Inc.	sold off	-100	-57,000	-	-%
2023-02-22	CVA Family Office, LLC	sold off	-100	-2,000	-	-%
2023-02-22	TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY	sold off	-100	-2,614,000	-	-%
2023-02-21	MACQUARIE GROUP LTD	added	111	84,553	163,553	-%

Latest Funds Activity

Are funds buying ELAN calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ELAN

No. of Funds

Elanco Animal Health News

Schedule 13G FIlings of Elanco Animal Health

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	dodge & cox	17.9%	84,775,075	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	4.0%	18,846,927	SC 13G/A
Feb 09, 2023	primecap management co/ca/	6.96%	32,983,562	SC 13G/A
Feb 09, 2023	vanguard group inc	9.64%	45,691,838	SC 13G/A
Feb 01, 2023	blackrock inc.	6.4%	30,546,195	SC 13G/A
Dec 22, 2022	sachem head capital management lp	2.0%	9,635,500	SC 13D/A
Nov 10, 2022	aristotle capital management, llc	0.30%	1,402,079	SC 13G/A
Sep 09, 2022	sachem head capital management lp	6.0%	28,635,500	SC 13D/A
Jul 08, 2022	dodge & cox	10.4%	49,206,190	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	7.3%	34,674,308	SC 13G/A

ELAN Fair Value

Elanco Animal Health fair value in different scenarios

The table shows the Fair Value estimates for Elanco Animal Health for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	3.93 -56.28%	4.93 -45.16%	6.72 -25.25%	10.27 14.24%	14.74 63.96%
Current Inflation	3.88 -56.84%	4.78 -46.83%	6.33 -29.59%	9.38 4.34%	13.21 46.94%
Very High Inflation	3.82 -57.51%	4.60 -48.83%	5.88 -34.59%	8.36 -7.01%	11.45 27.36%

Historical Elanco Animal Health Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Elanco Animal Health

View All Filings

Date Filed	Form Type	Document
Mar 24, 2023	3	Insider Trading
Mar 16, 2023	4	Insider Trading
Mar 15, 2023	4	Insider Trading
Mar 13, 2023	4	Insider Trading
Mar 07, 2023	4	Insider Trading
Mar 07, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading

Latest Insider Trading transactions for ELAN

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-15	YOUNG TODD S.	gifted	-	-	2,000	see remarks
2023-03-15	YOUNG TODD S.	gifted	-	-	-4,000	see remarks
2023-03-14	HOOVER R DAVID	bought	47,750	9.55	5,000	-
2023-03-14	YOUNG TODD S.	gifted	-	-	-118,309	see remarks
2023-03-14	YOUNG TODD S.	gifted	-	-	118,309	see remarks
2023-03-13	HOOVER R DAVID	bought	47,288	9.4576	5,000	-
2023-03-10	Simmons Jeffrey N	bought	143,972	9.5981	15,000	president, ceo and director
2023-03-05	Simmons Jeffrey N	sold (taxes)	-118,726	11.1	-10,696	president, ceo and director
2023-03-03	HOOVER R DAVID	bought	111,300	11.13	10,000	-

About Elanco Animal Health

Jeffrey N. Simmons

www.elanco.com

9800

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 4,411	$ 4,764	$ 3,271
Costs, expenses and other:
Cost of sales	1,913	2,132	1,667
Research and development	321	369	329
Marketing, selling and administrative	1,265	1,403	997
Amortization of intangible assets	528	556	360
Asset impairment, restructuring and other special charges	183	634	623
Interest expense, net of capitalized interest	241	236	150
Other (income) expense, net	32	5	(178)
Costs, expenses and other	4,483	5,335	3,948
Loss before income taxes	(72)	(571)	(677)
Income tax expense (benefit)	6	(88)	(103)
Net loss	$ (78)	$ (483)	$ (574)
Loss per share:
Basic (usd per share)	$ (0.16)	$ (0.99)	$ (1.30)
Diluted (usd per share)	$ (0.16)	$ (0.99)	$ (1.30)
Weighted average shares outstanding:
Basic (in shares)	488.3	487.2	441.4
Diluted (in shares)	488.3	487.2	441.4

ELAN Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 345	$ 638
Accounts receivable, net of allowances of $13 (2022) and $12 (2021)	797	833
Other receivables	205	195
Inventories	1,538	1,371
Prepaid expenses and other	394	237
Total current assets	3,279	3,274
Noncurrent Assets
Goodwill	5,993	6,172
Other intangibles, net	4,842	5,587
Other noncurrent assets	378	390
Property and equipment, net	999	1,055
Total assets	15,491	16,478
Current Liabilities
Accounts payable	390	416
Employee compensation	146	185
Sales rebates and discounts	324	319
Current portion of long-term debt	388	294
Other current liabilities	454	433
Total current liabilities	1,702	1,647
Noncurrent Liabilities
Long-term debt	5,448	6,025
Accrued retirement benefits	161	271
Deferred taxes	662	765
Other noncurrent liabilities	229	262
Total liabilities	8,202	8,970
Commitments and Contingencies
Equity
Preferred stock, 1,000,000,000 shares authorized, no par value; none issued	0	0
Common stock, 5,000,000,000 shares authorized, no par value; 474,237,738 and 473,119,786 shares issued and outstanding as of December 31, 2022 and 2021, respectively	0	0
Additional paid-in capital	8,738	8,696
Accumulated deficit	(1,057)	(979)
Accumulated other comprehensive loss	(392)	(209)
Total equity	7,289	7,508
Total liabilities and equity	$ 15,491	$ 16,478